Zhang Yunfei, Huang Fengchang, Xu Ning, Wang Jin, Li Dan, Yin Liang
Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
Department of Vascular Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming 650032, Yunnan, China.
Clinics (Sao Paulo). 2021 May 5;76:e2081. doi: 10.6061/clinics/2021/e2081. eCollection 2021.
Extracellular vesicle microRNAs (EV-miRNAs) have been demonstrated to be reliable candidate biomarkers for clinical applications. However, the clinical application potential of serum EV-miR-215-5p for gastric cancer (GC) remains poorly understood. The goal of our study was to determine the efficacy of serum EV-miR-215-5p in predicting the prognosis of GC.
Blood samples were collected from 118 patients with GC, 60 patients with benign gastric disease and BGD and 70 healthy controls. The relative levels of serum EV-miR-215-5p were measured using quantitative real-time polymerase chain reaction (qRT-PCR).
Compared to patients with BGD and normal controls, GC patients exhibited remarkably higher serum EV-miR-215-5p level, especially those with early tumor recurrence (ETR). Receiver operating characteristic (ROC) curve analysis showed that serum EV-miR-215-5p was able to distinguish GC patients from BGD patients or healthy controls and GC patients with ETR from those without ETR. In addition, increased serum EV-miR-215-5p levels were notably correlated with invasive depth, TNM stage, and lymph node metastasis. Moreover, serum EV-miR-215-5p levels were greatly decreased after surgical treatment, but increased at the time of ETR. Survival analysis showed that patients with higher serum EV-miR-215-5p had shorter survival. Furthermore, serum EV-miR-215-5p was an independent risk factor for GC.
Serum EV-miR-215-5p might be a novel biomarker for predicting ETR and prognosis of GC.
细胞外囊泡微小RNA（EV-miRNAs）已被证明是临床应用中可靠的候选生物标志物。然而，血清EV-miR-215-5p在胃癌（GC）中的临床应用潜力仍知之甚少。我们研究的目的是确定血清EV-miR-215-5p在预测GC预后方面的疗效。
收集118例GC患者、60例良性胃病（BGD）患者和70例健康对照者的血样。采用定量实时聚合酶链反应（qRT-PCR）检测血清EV-miR-215-5p的相对水平。
与BGD患者和正常对照相比，GC患者血清EV-miR-215-5p水平显著更高，尤其是早期肿瘤复发（ETR）患者。受试者工作特征（ROC）曲线分析表明，血清EV-miR-215-5p能够区分GC患者与BGD患者或健康对照，以及有ETR的GC患者与无ETR的患者。此外，血清EV-miR-215-5p水平升高与浸润深度、TNM分期和淋巴结转移显著相关。而且，手术治疗后血清EV-miR-215-5p水平大幅下降，但在ETR时升高。生存分析表明，血清EV-miR-215-5p水平较高的患者生存期较短。此外，血清EV-miR-215-5p是GC的独立危险因素。
血清EV-miR-215-5p可能是预测GC的ETR和预后的新型生物标志物。
